# CDC Supplement Year 3

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $498,837

## Abstract

ABSTRACT AND PROJECT SUMMARY
The purpose of this R01 proposal is to deepen our knowledge of the primary cause of drug overdose deaths in
the U.S. today: novel psychoactive synthetic opioids, the majority of which are fentanyl analogues. Using a
nationwide registry of patients who present to emergency departments, novel fentanyl analogue overdose will
be studied in terms of its epidemiology, analytical confirmation, clinical risk factors, and treatment needs, by a
uniquely qualified multidisciplinary team with an extensive track record of collaboration in the field.
The scope of the U.S. opioid epidemic is broadening, with drug overdose deaths nearly tripling from 1999-
2015. For the first time ever, in 2015 U.S. drug overdose deaths surpassed 50,000 (52,404), of which 33,091
(63.1%) involved an opioid. Overdose deaths continued to increase in 2016 to 63,600. Opioid overdoses cost
Americans $504 billion in 2015 (2.8% of gross domestic product), up from six times the prior estimates in 2013.
There was a 27% increase in nationwide Emergency Department visits for opioid overdoses last year alone.
Strategies to mitigate this trend by decreasing the availability and abuse potential of prescription opioids have
been followed by an increase in illicit opioid use. While initially the predominance of illicit opioid overdoses
were a result of heroin exposure, the changing face of global drug commerce introduced synthetic opioid
fentanyl analogues into the drug supply, where they are now estimated to have surpassed heroin as the
primary cause of drug overdose deaths.
Using nearly 70 hospital centers nationwide with bedside evaluation of patients, over 10,000 overdose patients
have been enrolled in the Principal Investigator’s prior study giving this proposal momentum and feasibility.
Our specific aims are four-fold: (1) state-of-the-art toxicology analytics, as well as biomarkers of clinical
severity; (2) treatment requirements such as naloxone, need for critical care and/or mechanical ventilation; and
(3) regional and temporal trends nationwide to be shared via the CDC website for nonfatal drug overdose.
To achieve these Specific Aims, we will increase enrollment of an ongoing, national sample of patients. We will
implement the rapid dissemination of alerts and information to the public and public health entities on adverse
effects of fentanyl analogues. At the completion of the proposed research, the knowledge of emerging
substances will be significantly advanced to the benefit of thousands of victims of the U.S. opioid epidemic.

## Key facts

- **NIH application ID:** 10993749
- **Project number:** 3R01DA048009-05S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Alex Francis Manini
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $498,837
- **Award type:** 3
- **Project period:** 2020-04-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10993749

## Citation

> US National Institutes of Health, RePORTER application 10993749, CDC Supplement Year 3 (3R01DA048009-05S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10993749. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*